Immune therapy doubles lung cancer survival rate
April 17, 2018
New drugs that trigger a patient’s immune system to kill malignant cells can greatly improve the survival rate of people with the most common type of lung cancer, a new study found. The study, published in the New England Journal of Medicine, found that patients treated with the checkpoint inhibitor pembrolizumab, or Keytruda,...
Wochit News - ▶ 00:45
Wochit News - ▶ 00:32
Recent related news
For the first time, a treatment that boosts the immune system greatly improved survival in people newly diagnosed with the most common form of lung cancer. It's...
1 week ago • CBC.ca